Monthly Intravitreal Bevacizumab for Macular Edema after Iodine-125 Plaque Radiotherapy of Uveal Melanoma

2014 ◽  
Vol 24 (2) ◽  
pp. 228-234 ◽  
Author(s):  
Arman Mashayekhi ◽  
Duangnate Rojanaporn ◽  
Saad Al-Dahmash ◽  
Carol L. Shields ◽  
Jerry A. Shields
Keyword(s):  
Macular Edema ◽  
Uveal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Plaque Radiotherapy ◽  
Iodine 125

Periocular Triamcinolone for Prevention of Macular Edema After Iodine 125 Plaque Radiotherapy of Uveal Melanoma

Retina ◽  
2008 ◽  
Vol 28 (7) ◽  
pp. 987-995 ◽  
Author(s):  
Noel Horgan ◽  
Carol L. Shields ◽  
Arman Mashayekhi ◽  
Luiz F. Teixeira ◽  
Miguel A. Materin ◽  
...  
Keyword(s):  
Macular Edema ◽  
Uveal Melanoma ◽  
Plaque Radiotherapy ◽  
Iodine 125

Intravitreal Bevacizumab at 4-Month Intervals for Prevention of Macular Edema after Plaque Radiotherapy of Uveal Melanoma

Ophthalmology ◽  
2014 ◽  
Vol 121 (1) ◽  
pp. 269-275 ◽  
Author(s):  
Sanket U. Shah ◽  
Carol L. Shields ◽  
Carlos G. Bianciotto ◽  
Juan Iturralde ◽  
Saad A. Al-Dahmash ◽  
...  
Keyword(s):  
Macular Edema ◽  
Uveal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Plaque Radiotherapy

Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma

Ophthalmology ◽  
2017 ◽  
Vol 124 (10) ◽  
pp. 1532-1539 ◽  
Author(s):  
Prithvi Mruthyunjaya ◽  
Michael I. Seider ◽  
Sandra Stinnett ◽  
Amy Schefler ◽  
Prithvi Mruthyunjaya ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profile ◽  
Uveal Melanoma ◽  
Expression Profile ◽  
Tumor Regression ◽  
Regression Rate ◽  
Plaque Radiotherapy ◽  
Iodine 125

Periocular Triamcinolone for Prevention of Macular Edema after Plaque Radiotherapy of Uveal Melanoma

Ophthalmology ◽  
2009 ◽  
Vol 116 (7) ◽  
pp. 1383-1390 ◽  
Author(s):  
Noel Horgan ◽  
Carol L. Shields ◽  
Arman Mashayekhi ◽  
Pedro F. Salazar ◽  
Miguel A. Materin ◽  
...  
Keyword(s):  
Macular Edema ◽  
Uveal Melanoma ◽  
Plaque Radiotherapy

SECTOR LASER PHOTOCOAGULATION FOR THE PREVENTION OF MACULAR EDEMA AFTER PLAQUE RADIOTHERAPY FOR UVEAL MELANOMA

Retina ◽  
2012 ◽  
Vol 32 (8) ◽  
pp. 1601-1607 ◽  
Author(s):  
Miguel A. Materin ◽  
Carlos G. Bianciotto ◽  
Chengqing Wu ◽  
Carol L. Shields
Keyword(s):  
Macular Edema ◽  
Uveal Melanoma ◽  
Laser Photocoagulation ◽  
Plaque Radiotherapy

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

2019 ◽  
Vol 104 (5) ◽  
pp. 697-702 ◽  
Author(s):  
Lauren A Dalvin ◽  
Qiang Zhang ◽  
Rose A Hamershock ◽  
Michael Chang ◽  
Michael D Yu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Visual Acuity ◽  
Uveal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Insulin Dependent Diabetes ◽  
Clinical Risk Factors ◽  
Tumour Thickness ◽  
Treatment Risk ◽  
Plaque Radiotherapy ◽  
Insulin Dependent

AimsTo develop a nomogram for prediction of visual acuity outcome following plaque radiotherapy for uveal melanoma.MethodsRetrospective review of uveal melanoma treated with plaque radiotherapy and prophylactic intravitreal bevacizumab injections at 4-month intervals for 2 years duration. Two nomograms for poor visual acuity outcome (Snellen <20/200) were developed based on (1) Clinical risk factors. (2) Or clinical and treatment risk factors.ResultsThere were 1131 included cases. The most important clinical risk factors (points for nomogram) for poor visual acuity outcome included subretinal fluid involving four quadrants (100), tumour thickness >4 mm (69), presenting visual acuity ≤20/30 (65), non-Caucasian race (58), tumour shape mushroom, bilobed, or multilobulated (57), and insulin-dependent diabetes (54). Risk of poor visual acuity at 2 years and 4 years increased from 11% and 24% with 40 points to 97% and >99% with 304 points. A second analysis was performed using both clinical and treatment risk factors. The most important factors included presenting visual acuity ≤20/30 (100), tumour largest basal diameter >11 mm (80), radiation dose rate to tumour base ≥164 cGy/hour (78), tumour thickness >4 mm (76), insulin-dependent diabetes (75) and abnormal foveolar status by optical coherence tomography at presentation (72). Risk of poor visual acuity at 2 years and 4 years increased from 6% and 14% with 56 points to 88% and 99% with 496 points.ConclusionsA nomogram using clinical or treatment risk factors can predict visual acuity outcome following plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma and is available online at https://fighteyecancer.com/nomograms/.

INTRAVITREAL BEVACIZUMAB TREATMENT FOR RADIATION MACULAR EDEMA AFTER PLAQUE RADIOTHERAPY FOR CHOROIDAL MELANOMA

Retina ◽  
2007 ◽  
Vol 27 (7) ◽  
pp. 903-907 ◽  
Author(s):  
JOHN O. MASON ◽  
MICHAEL A. ALBERT ◽  
TAREK O. PERSAUD ◽  
RACHEL S. VAIL
Keyword(s):  
Macular Edema ◽  
Choroidal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Bevacizumab Treatment ◽  
Plaque Radiotherapy

scholarly journals Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma

2020 ◽  
Vol 138 (2) ◽  
pp. 136 ◽  
Author(s):  
Carol L. Shields ◽  
Lauren A. Dalvin ◽  
Michael Chang ◽  
Mehdi Mazloumi ◽  
Patricia Fortin ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Plaque Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document